Welcome to AAMC  

Mission

Patient Resources

Medical Uses

News

Recipes

Search

Message Board

Contribute

Links

Contact

 

delta 9-tetrahydrocannabinol in clinical oncology.

Poster DS, Penta JS, Bruno S, Macdonald JS
JAMA 1981 May 22-29; 245(20):2047-51

After anecdotal reports of marijuana's providing antiemetic activity in cancer chemotherapy patients refractory to standard agents, orally administered delta 9-tetrahydrocannabinol (THC) was formally studied by a number of investigators. In six of seven well-controlled studies, orally administered THC was a superior antiemetic agent compared with control agents. The THC toxic effects are notable but manageable. Patients rarely require hospitalization after the development of THC-induced dysphorias. However, serious toxic effects are uncommon and the most frequently noted effects are somnolence, conjunctivitis, and tachycardias. Because certain subgroups of patients are more prone to have toxicities develop, careful selection of the candidates to receive this agent is mandatory. Overall, the benefits of orally administered THC use represent a major advance in antiemetic therapy.

Cancer References: ACS : American Cancer Society

Medical References: National Library of Medicine - PubMed



Distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

     
   

Click here to refer this page to a friend and let freedom grow

Home | Mission | Patient Resources | News & Events | Recipes
Search | Message Board | Medical Uses | Contribute | Links | Contact


Copyright 2001-2007 American Alliance for Medical Cannabis, Inc. All rights reserved.